Key terms

About IQV

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IQV news

May 03 11:28am ET IQVIA Holdings (IQV) Gets a Buy from Bank of America Securities May 03 8:16am ET Buy Rating Affirmed for IQVIA Holdings Amidst Strong Growth and Resilient Demand May 03 7:45am ET IQVIA Holdings (IQV) Receives a Buy from Truist Financial May 03 6:23am ET Iqvia price target lowered to $245 from $254 at Baird May 02 7:27am ET Iqvia backs FY24 adjusted EPS view $10.95-$11.25, consensus $11.11 May 02 7:23am ET Iqvia reports Q1 EPS $2.54, consensus $2.48 Apr 17 10:35am ET Bank of America Securities Reaffirms Their Buy Rating on IQVIA Holdings (IQV) Apr 09 7:35am ET Truist Financial Reaffirms Their Buy Rating on IQVIA Holdings (IQV) Apr 08 4:01pm ET Iqvia, Salesforce expand global partnership Mar 29 3:20am ET Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM) Mar 06 8:06am ET Truist Financial Sticks to Their Buy Rating for IQVIA Holdings (IQV) Feb 28 7:55am ET Iqvia price target raised to $300 from $260 at Argus Feb 27 9:11am ET Iqvia price target raised to $297 from $286 at Truist Feb 27 7:41am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), IQVIA Holdings (IQV) and Bausch Health Companies (BHC) Feb 26 7:20am ET Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK) Feb 26 6:18am ET Iqvia initiated with an Outperform at Leerink Feb 23 7:00am ET Iqvia price target raised to $268 from $242 at Mizuho Feb 20 8:41am ET Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), IQVIA Holdings (IQV) and Ascendis Pharma (ASND) Feb 19 5:30am ET Analysts’ Top Healthcare Picks: IQVIA Holdings (IQV), Denali Therapeutics (DNLI) Feb 19 12:51am ET Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), SAGE Therapeutics (SAGE) and IQVIA Holdings (IQV) Feb 15 8:26am ET Iqvia downgraded to Neutral at Guggenheim on valuation Feb 15 8:14am ET Iqvia price target raised to $265 from $255 at Evercore ISI Feb 15 7:56am ET Iqvia price target raised to $270 from $239 at TD Cowen Feb 15 7:53am ET Iqvia price target raised to $300 from $240 at UBS Feb 15 7:37am ET Iqvia price target raised to $290 from $285 at BTIG Feb 15 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 15 6:17am ET IQVIA Holdings: A Strong Buy on Robust TAS Growth and RDS Stability Feb 15 6:15am ET Iqvia downgraded to Neutral from Buy at Guggenheim Feb 15 3:10am ET Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Evolent Health (EVH) and InMode (INMD) Feb 14 10:26am ET Iqvia shares up 10% to $236.09 after Q4 earnings beat estimates Feb 14 10:25am ET Iqvia sees FY24 adjusted EPS $10.95-$11.25, consensus $11.07

No recent press releases are available for IQV

IQV Financials

1-year income & revenue

Key terms

IQV Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IQV Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms